Renhuang Pharmaceuticals Develops Anti-Depression Drug
Posted on: Wednesday, 23 January 2008, 12:01 CST
Renhuang Pharmaceuticals has announced the successful laboratory production of lyophilized syringin powder, its new powder injection anti-depression and fatigue drug.
Lyophilized syringin powder for injection is developed independently by Renhuang as a new form of pure Chinese herbal medicine that does not have any of the side-effects of other synthetic anti-depression drugs commonly used by patients around the world. Renhuang is in the process to file an invention patent application for this new drug with the State Intellectual Property Office of the PRC. The product is expected to be classified as a 'Class One' new drug by SFDA representing a major breakthrough in anti-depression drug development worldwide. This new drug can also be used as anti-exhaustion treatment, wound stancher and healthy gland growth nutrition.
At 90% purity, the syringin portion in the sample drugs meets the criteria of the State Food and Drug Administration. Renhuang is expected to soon start clinical trials to evaluate both the efficacy and the safety of this new drug for depression and fatigue patients.
Li Shaoming, CEO of Renhuang, said: "We are very confident that this new drug will not only help Renhuang expand its market share in China but it will also increase its brand awareness overseas."
Source: Datamonitor
Related Articles
- Renhuang Pharmaceuticals Announces Breakthrough in Study of New Form of Anti-Depression Chinese Medicine: Lyophilized Syringin Powder for Injection
- VGX Pharmaceuticals Receives FDA Clearance to Commence Clinical Trials of VGX-1027, a Novel Oral Drug With Potent Anti-Inflammatory Activity
- Epix Tests Drug for Depression/Anxiety
- The Market for Antidepressive Drugs Is the Largest Segment of the CNS Sector With Global Sales of US$16.2 Billion in 2005 - 2006 Market Research CNS Drug Discoveries: Depression
- Therapy, Not Drugs, for Depressed Seniors
- Study Shows Link Between Acne Drug and Depression
- Wyeth Drug Improves Depression Symptoms in Phase III Trial
- GSK's HIV Drug to Carry Anti-Fake ID Tags
- FDA Grants Orphan Drug Status for Anti-Anthrax Drug
- Youngsters Use More Drugs for Depression
User Comments (0)

RSS Feeds